Page last updated: 2024-09-03

gefitinib and bms 387032

gefitinib has been researched along with bms 387032 in 7 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(bms 387032)
Trials
(bms 387032)
Recent Studies (post-2010) (bms 387032)
5,2315662,91976356

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)bms 387032 (IC50)
Cyclin-T1Homo sapiens (human)0.0103
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.48
G1/S-specific cyclin-E2Homo sapiens (human)0.048
Vitamin K-dependent protein CHomo sapiens (human)0.264
Cyclin-dependent kinase 1Homo sapiens (human)0.48
Cyclin-dependent kinase 4Homo sapiens (human)0.7538
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.48
Cyclin-A2Homo sapiens (human)0.0427
G1/S-specific cyclin-D1Homo sapiens (human)0.925
G1/S-specific cyclin-E1Homo sapiens (human)0.046
Cyclin-dependent kinase 2Homo sapiens (human)0.0426
G1/S-specific cyclin-D2Homo sapiens (human)0.925
G1/S-specific cyclin-D3Homo sapiens (human)0.925
Cannabinoid receptor 2Mus musculus (house mouse)0.062
Cyclin-dependent kinase 7Homo sapiens (human)0.0772
Cyclin-dependent kinase 9Homo sapiens (human)0.1078
Cyclin-HHomo sapiens (human)0.0823
CDK-activating kinase assembly factor MAT1Homo sapiens (human)0.1027
Cyclin-A1Homo sapiens (human)0.021
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.34
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.34
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.48

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Cai, GX; Chen, GX; Chen, X; Deng, YF; Huang, HB; Kong, WY; Lei, QC; Liao, YN; Liu, Y; Shao, ZL; Sun, WS; Wang, R; Wu, SG; Yu, CF; Zhuang, XF1

Other Studies

7 other study(ies) available for gefitinib and bms 387032

ArticleYear
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16.
    Acta pharmacologica Sinica, 2023, Volume: 44, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Homeodomain Proteins; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Ribosomal Proteins; Sorafenib

2023
chemdatabank.com